Contrast Media & Molecular Imaging

Cover image for Contrast Media & Molecular Imaging

September/October 2009

Volume 4, Issue 5

Pages 207–255

  1. Reviews

    1. Top of page
    2. Reviews
    3. Full Papers
    4. Current Awareness
    1. Assessing cytotoxicity of (iron oxide-based) nanoparticles: an overview of different methods exemplified with cationic magnetoliposomes (pages 207–219)

      Stefaan J. H. Soenen and Marcel De Cuyper

      Version of Record online: 6 OCT 2009 | DOI: 10.1002/cmmi.282

      Thumbnail image of graphical abstract

      For efficient MR contrast abilities, stem or therapeutic cells are often pre-labelled in vitro with iron oxide nanoparticles to enable subsequent cell tracking in vivo. This labelling can cause cytotoxic effects or lead to more subtle effects on cell physiology, which can be hard to monitor. Herein, we elaborate on different assays which can be used, highlight their shortcomings and potential pitfalls, and provide possible solutions to any encountered problem. We also discuss the important link between intracellular nanoparticle concentration and cytotoxicity.

  2. Full Papers

    1. Top of page
    2. Reviews
    3. Full Papers
    4. Current Awareness
    1. Effect of a mesitylene-based ligand cap on the relaxometric properties of Gd(III) hydroxypyridonate MRI contrast agents (pages 220–229)

      Eric J. Werner, Mauro Botta, Silvio Aime and Kenneth N. Raymond

      Version of Record online: 16 OCT 2009 | DOI: 10.1002/cmmi.281

      Thumbnail image of graphical abstract

      A series of new hydroxypyridonate Gd(III) complexes featuring a mesitylene (ME)-derived ligand cap has been prepared. Relaxometric characterization reveals that the complexes tend to form large aggregates in solution with slow tumbling rates, as estimated from NMRD analysis, and unique pH-dependent relaxivities. The solution behavior and relaxometric properties are compared with those observed for analogous TREN-capped compounds, and the potential for use of these new ME-capped complexes as pH-responsive MRI contrast agents is explored.

    2. Ferumoxides–protamine sulfate is more effective than ferucarbotran for cell labeling: implications for clinically applicable cell tracking using MRI (pages 230–236)

      G. M. van Buul, E. Farrell, N. Kops, S. T. van Tiel, P. K. Bos, H. Weinans, G. P. Krestin, G. J. V. M. van Osch and M. R. Bernsen

      Version of Record online: 16 OCT 2009 | DOI: 10.1002/cmmi.289

      Thumbnail image of graphical abstract

      In this study we performed a direct comparison of two SPIO labeling approaches of ferumoxides–protamine complexes vs ferucarabotran on primary human bone marrow stromal cells and chondrocytes. For both cell types ferumoxides–protamine resulted in a higher percentage of labeled cells, a higher total iron load, a higher amount of intracellular iron and a lower amount of extracellular iron aggregates, compared with ferucarbotran. We showed ferumoxides–protamine to be a more effective and specific cell labeling method over ferucarbotran for both cell types.

    3. Methods for an improved detection of the MRI-CEST effect (pages 237–247)

      Enzo Terreno, Joseph Stancanello, Dario Longo, Daniela Delli Castelli, Luciano Milone, Honorius M. H. F. Sanders, Maarten B. Kok, Fulvio Uggeri and Silvio Aime

      Version of Record online: 16 OCT 2009 | DOI: 10.1002/cmmi.290

      Thumbnail image of graphical abstract

      Methods for calculating the magnitude of MR-CEST contrast have been developed and tested in silico, in vitro and in vivo. The net improvement obtained by applying the proposed methods with respect to the currently used, standard, CEST assessment relies on the exploitation of the Z-spectrum data. The new approaches lower the detection threshold of CEST agents, thus improving the overall potential of these agents.

  3. Current Awareness

    1. Top of page
    2. Reviews
    3. Full Papers
    4. Current Awareness

SEARCH

SEARCH BY CITATION